Further Reading

 

Biological Roles of Glycans

  • Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019 Jun;15(6):346-366. 

Sialic Acid-Mediated Therapy

  • Bednar KJ, Nycholat CM, Rao TS, Paulson JC, Fung-Leung WP, Macauley MS. Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis. ACS Chem Biol. 2019 Apr 19;14(4):644-654.
  • Duan S, Paulson JC. Siglecs as Immune Cell Checkpoints in Disease. Annu Rev Immunol. 2020 Apr 26;38:365-395. 
  • Finke JM, Ayres KR, Brisbin RP, Hill HA, Wing EE, Banks WA. Antibody blood-brain barrier efflux is modulated by glycan modification. Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2228-2239.
  • Lübbers J, Rodríguez E, van Kooyk Y. Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions. Front Immunol. 2018 Dec 7;9:2807. 
  • Perdicchio M, Ilarregui JM, Verstege MI, Cornelissen LA, Schetters ST, Engels S, Ambrosini M, Kalay H, Veninga H, den Haan JM, van Berkel LA, Samsom JN, Crocker PR, Sparwasser T, Berod L, Garcia-Vallejo JJ, van Kooyk Y, Unger WW. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells. Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3329-34. 

Glycan-Mediated Protein Degradation

  • Cummings RD, McEver RP. C-Type Lectins. 2017. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology [Internet]. 3rd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015-2017. Chapter 34. Available from: https://www.ncbi.nlm.nih.gov/books/NBK453028/ 
  • D'Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J Control Release. 2015 Apr 10;203:126-39. 

Glycan-Targeted Immuno Therapy 

  • Mereiter S, Balmaña M, Campos D, Gomes J, Reis CA. Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? Cancer Cell. 2019 Jul 8;36(1):6-16.

Enhanced Fc effector functions through a fully afucosylated N-glycan for monoclonal antibody applications

  • Bloemendaal FM, Levin AD, Wildenberg ME, Koelink PJ, McRae BL, Salfeld J, Lum J, van der Neut Kolfschoten M, Claassens JW, Visser R, Bentlage A, D'Haens GRAM, Verbeek JS, Vidarsson G, van den Brink GR. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis. Gastroenterology. 2017 Nov;153(5):1351-1362.